Compare BFH & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFH | BLTE |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | N/A | 2022 |
| Metric | BFH | BLTE |
|---|---|---|
| Price | $69.12 | $166.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | $68.53 | ★ $161.57 |
| AVG Volume (30 Days) | ★ 924.3K | 237.7K |
| Earning Date | 01-29-2026 | 03-16-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | ★ 9.68 | N/A |
| Revenue | ★ $2,509,000,000.00 | N/A |
| Revenue This Year | $58.62 | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $7.17 | ★ N/A |
| Revenue Growth | ★ 1.70 | N/A |
| 52 Week Low | $38.21 | $49.00 |
| 52 Week High | $82.03 | $174.78 |
| Indicator | BFH | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 63.97 |
| Support Level | $68.07 | $156.52 |
| Resistance Level | $70.80 | $174.78 |
| Average True Range (ATR) | 2.26 | 8.80 |
| MACD | -0.72 | 0.13 |
| Stochastic Oscillator | 9.19 | 73.96 |
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.